HTFL
Heartflow, Inc. Common Stock NASDAQ Listed Aug 7, 2025$33.64
+2.44%
vs $32.84
Mkt Cap $12.4B
52w Low $20.49
67.7% of range
52w High $39.91
50d MA $29.90
200d MA $30.02
P/E (TTM)
-24.6x
EV/EBITDA
—
P/B
41.2x
Debt/Equity
0.1x
ROE
-38.9%
P/FCF
-210.0x
RSI (14)
62.30
ATR (14)
$1.90
Beta
1.03
50d MA
$29.90
200d MA
$30.02
Avg Volume
1.2M
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company's platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. The company was founded in 2007 and is headquartered in Mountain View, California.
331 E. Evelyn Avenue · Mountain View, CA 94041 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.17 | -0.12 | +31.3% | 25.47 | -1.8% | +1.6% | +0.5% | +3.1% | +4.3% | -0.8% | — |
| Nov 12, 2025 | AMC | -0.20 | -0.27 | -35.0% | 35.74 | -3.0% | -13.4% | -9.6% | -5.6% | +3.4% | -0.3% | — |
| Sep 19, 2025 | AMC | -0.20 | -1.46 | -630.0% | 32.88 | -0.8% | -4.4% | +14.1% | -3.8% | -1.7% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | William Blair | Initiates | Outperform | — | $28.67 | $28.99 | +1.1% | +1.0% | +3.5% | +1.1% | -1.0% | -1.6% |
| Mar 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $25.47 | $25.00 | -1.8% | +1.6% | +0.5% | +3.1% | +4.3% | -0.8% |
| Mar 19 | JP Morgan | Maintains | Overweight → Overweight | — | $25.47 | $25.00 | -1.8% | +1.6% | +0.5% | +3.1% | +4.3% | -0.8% |
| Mar 19 | Wells Fargo | Maintains | Overweight → Overweight | — | $25.47 | $25.00 | -1.8% | +1.6% | +0.5% | +3.1% | +4.3% | -0.8% |
| Mar 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $22.98 | $23.09 | +0.5% | +0.9% | -2.5% | -1.7% | -6.4% | -1.4% |
| Nov 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $35.74 | $34.65 | -3.0% | -13.4% | -9.6% | -5.6% | +3.4% | -0.3% |
| Nov 13 | JP Morgan | Maintains | Overweight → Overweight | — | $35.74 | $34.65 | -3.0% | -13.4% | -9.6% | -5.6% | +3.4% | -0.3% |
| Nov 13 | Stifel | Maintains | Buy → Buy | — | $35.74 | $34.65 | -3.0% | -13.4% | -9.6% | -5.6% | +3.4% | -0.3% |
| Sep 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $32.88 | $32.62 | -0.8% | -4.4% | +14.1% | -3.8% | -1.7% | -2.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Rogers CampbellOff | Chief Medical Officer | Sell | 9,219 | $28.34 | $261K | 78,731 | +6.65% | +8.37% |
| May 11, 2026 | Farquhar John C.M.Dir/Off | Chief Executive Officer | Sell | 22,562 | $29.12 | $657K | 519,397 | +3.33% | +2.93% |
| Apr 30, 2026 | Bain Capital Life Sciences Investors, LLC | — | Sell | 56,224 | $30.05 | $1.7M | 8,448,158 | -3.66% | -1.02% |
| Apr 30, 2026 | Bain Capital Life Sciences Investors, LLC | — | Sell | 892,533 | $29.18 | $26.0M | 8,504,382 | -3.66% | -1.02% |
| Apr 29, 2026 | Bain Capital Life Sciences Investors, LLC | — | Sell | 797,133 | $29.37 | $23.4M | 9,396,915 | -3.66% | -1.02% |
| Apr 28, 2026 | Bain Capital Life Sciences Investors, LLC | — | Sell | 254,110 | $30.51 | $7.8M | 10,194,048 | -3.66% | -1.02% |
8-K · 2.02
!! High
Heartflow, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K
Unknown — 8-K Filing
HeartFlow's full-year 2025 results will reveal revenue growth, profitability progress, and whether AI-driven cardiac imaging adoption is accelerating—critical metrics for valuing this high-growth medical technology company.
Mar 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 5,397,802 | $131M | Added | Mar 2026 |
| 2 | Janus Henderson Group Plc | 2,180,976 | $53M | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 2,045,938 | $50M | New | Mar 2026 |
| 4 | Invesco Ltd. | 1,913,090 | $47M | Added | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,893,495 | $46M | New | Mar 2026 |
| 6 | Morgan Stanley | 1,491,848 | $43M | Reduced | Dec 2025 |
| 7 | Millennium Management | 1,093,417 | $27M | Added | Mar 2026 |
| 8 | Franklin Resources Inc | 793,721 | $19M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 756,605 | $18M | Reduced | Mar 2026 |
| 10 | Ensign Peak Advisors, Inc | 690,466 | $17M | Reduced | Mar 2026 |
| 11 | Next Century Growth Investors Llc | 652,969 | $16M | New | Mar 2026 |
| 12 | Champlain Investment Partners, Llc | 567,424 | $14M | New | Mar 2026 |
| 13 | Point72 Asset Management | 538,351 | $13M | Added | Mar 2026 |
| 14 | Rtw Investments, Lp | 495,000 | $12M | — | Mar 2026 |
| 15 | Lord, Abbett & Co. Llc | 450,364 | $11M | Reduced | Mar 2026 |
| 16 | Jpmorgan Chase & Co | 446,985 | $11M | Reduced | Mar 2026 |
| 17 | Ubs Group Ag | 429,084 | $10M | Reduced | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 342,809 | $8M | Added | Mar 2026 |
| 19 | Xxec, Inc. | 278,681 | $8M | Added | Mar 2026 |
| 20 | Voya Investment Management Llc | 228,617 | $7M | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$12.40B
Enterprise Value
$12.24B
P/E (TTM)
-24.55x
Forward P/E
—
PEG Ratio
11.42x
P/B
41.24x
P/S
70.43x
P/FCF
-209.96x
EV/EBITDA
—
Shares Out
368.5M
Financials (TTM)
Revenue
$176.0M
Net Income
-$116.8M
EBITDA
-$55.5M
Free Cash Flow
-$59.0M
Op Cash Flow
-$54.0M
EPS Basic
$-1.37
EPS Diluted
$-1.37
EPS Forward
$-0.56
Gross Margin
76.8%
Op Margin
-36.4%
Net Margin
-66.3%
Balance Sheet
Total Assets
$359.5M
Total Liab.
$58.8M
Total Equity
$300.6M
Cash
$176.8M
LT Debt
$16.1M
Book Value/Sh
$0.82
Debt/Equity
0.07x
Current Ratio
5.20
Quick Ratio
5.20
Returns & Growth
ROE
-38.9%
ROA
-32.5%
ROIC
-19.8%
Rev Growth YoY
+39.9%
EPS Growth YoY
+8.1%
Price Returns
2W
-3.9%
1M
+4.1%
3M
+33.8%
6M
-3.9%
12M
+7.8%
Technicals
52W High
$39.91
52W Low
$20.49
50d MA
$29.90
200d MA
$30.02
RSI (14)
62.30
ATR (14)
$1.90
Beta
1.03
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$38.00
High
$38.00
Low
$38.00
Median
$38.00
Data updated apr 25, 2026 2:13pm
· Source: financialmodelingprep.com